Since 1/2019 health insurance in Czechia partly covers consumables for using Flash Glucose Monitoring (FGM) for every patient with T1D.Aim of the study is to compare parameters of metabolic control of glycaemia in T1D patients after 3 and 6-9 months of using FGM based on retrospective CGM analyses and to check patients’ knowledge on using the sensor and their satisfaction with the sensor.
27 patients with T1D (mean age 47.3, mean HbA1C 59.7 mmol/mol, 13 males, 15 CSII/12 MDI) using FGM since 1/2019 filled in 8-9/2019 a questionnaire on: technical aspects of using sensor, data interpretation, general educational principles, Gold score, DDS2 and satisfaction with use (GMSS-total score, four subscales). Clinical data (TIR, TBR, GMI, HbA1C) were obtained from medical documentation and from two retrospective CGM analyses over period of 3-6 months produced before regular medical check-up.
Use of FGM proved a positive trend in prolonging the time-in-range period (TIR) for 4.1% (p=0,052). In the second CGM analysis target values of TIR>70% were reached by 3 patients (11.1%), while in the first one it was only 1 patient (3.7%). Average knowledge score was 39.7 (range of 0-54), average overall satisfaction score 61.7 (range of 15-75).
Improvement of metabolic control of glycaemia in our patient group on FGM didn´t reach statistical significance. The probable reason is short monitoring period and uneven interval between assessed CGM analyses. A certain positive trend was however observed. Effective use of FGM requires education and engagement of both patients and clinicians.